SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Policy
Johnson & Johnson Coughs Up $33 Million Over Recalled Nonprescription Meds
May 25, 2017
 · 
1 min read
Johnson & Johnson Dissolves $700 Million R&D Deal With MacroGenics
Policy
Confident Johnson & Johnson Flexes Its Muscles, Plans 10 Blockbuster Approvals by 2021
May 17, 2017
 · 
3 min read
Pharm Country
FDA Warns of Leg, Foot Amputations With Johnson & Johnson’s Diabetes Med, Invokana
May 17, 2017
 · 
1 min read
Policy
Johnson & Johnson Reveals U.S Investigation Into Arthritis Drug Services
May 9, 2017
 · 
1 min read
Policy
Former Johnson & Johnson Exec Wins Appeal In Noncompete Spat With Baxter International
May 4, 2017
 · 
1 min read
Policy
Johnson & Johnson Hit With $20 Million Verdict in Philly Pelvic Mesh Trial as More Lawsuits Loom
May 1, 2017
 · 
1 min read
Interview Insider: Tips on How to Get Hired at Johnson & Johnson, Novartis, and Bristol-Myers Squibb
Biotech Bay
Interview Insider: Tips on How to Get Hired at Johnson & Johnson, Bristol-Myers Squibb, and Novartis AG
April 28, 2017
 · 
6 min read
Business
Johnson & Johnson Snags $260 Million Orthopedic Devices Contract With the Pentagon
April 28, 2017
 · 
1 min read
Pharm Country
Why Risk-Averse Investors May Want To Think Twice About Buying Johnson & Johnson
April 26, 2017
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Press Releases
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
December 8, 2025
 · 
15 min read
Load More